Patient Access to Lab Services

Coinsurance would disrupt the ability of health care practitioners to work with their patients to ascertain the best lab tests to help best diagnose new conditions, manage existing conditions, and guide therapy, which is critical for the Medicare population as they often have multiple comorbidities. Currently, since there is no cost-sharing, patients who need more…

Coinsurance would disrupt the ability of health care practitioners to work with their patients to ascertain the best lab tests to help best diagnose new conditions, manage existing conditions, and guide therapy, which is critical for the Medicare population as they often have multiple comorbidities. Currently, since there is no cost-sharing, patients who need more lab tests due to more complicated health conditions have no greater financial risk than patients those with less complex conditions when receiving their lab results – and a patient may not know whether their condition is simple or complex when they first see a doctor. Despite this common-sense approach, some policy-makers calling for entitlement reform and deficit reduction have proposed putting into place a new 20% patient coinsurance for clinical laboratory services as an attempt to make Medicare beneficiaries more aware of health care costs. In real life, coinsurance for lab services will dis-incentivize Medicare beneficiaries from receiving timely and life-saving clinical lab tests, thus increasing health care costs through worse outcomes, and would drastically increase the cost of providing lab services through generating millions of new patient bills.

Read More

  • ACLA Files A Motion for Summary Judgment Against HHS In ACLA v. Azar

    October 15, 2019
    Washington, D.C. — Following a favorable decision on a jurisdictional question issued by the U.S. Court of Appeals for the D.C. Circuit, the American Clinical Laboratory Association (ACLA) has filed a motion for summary judgment before the U.S. District Court for the District of Columbia challenging the flawed implementation of the Protecting Access to Medicare Act (PAMA) in the final rule promulgated by the U.S. DepartmentContinue Reading »...
  • More than 60 Leading Health Care Organizations Call on CMS to Maintain Coverage for Medically Necessary Cancer Testing

    February 01, 2019
    Overly broad interpretation of national coverage determination for next generation sequencing restricts Medicare beneficiary access to vital testing and adversely impacts cancer care  WASHINGTON, DC – February 1, 2019 – Leading health care companies and organizations representing patients, providers, academic medical centers, laboratories, and diagnostic manufacturers urged the Centers for Medicare and Medicaid Services (CMS) to revise its interpretation of the National Coverage DeterminationContinue Reading »...
  • ACLA Urges Summary Judgment from District Court on Lawsuit Against HHS

    April 09, 2018
    Lawsuit targets HHS’ unlawful implementation of 2014 Medicare legislation, regulation that would jeopardize beneficiaries’ access to critical lab services Washington, D.C. – With millions of Medicare beneficiaries facing potential shortages in critical laboratory tests and diagnostics, the American Clinical Laboratory Association (ACLA) continued the push for summary judgment in its lawsuit against the U.S. Department of Health and Human Services (HHS) for failing toContinue Reading »...
  • ACLA VS. AZAR – Reply in Support of Motion for Summary Judgment

    April 09, 2018
    ...
  • ACLA Supportive of CMS Revisions to National Coverage Determination on the Use of Next Generation Sequencing in Cancer

    March 23, 2018
    (Washington, D.C.) – The American Clinical Laboratory Association (ACLA) expressed support today for revisions made by the Centers for Medicare and Medicaid Services (CMS) to the final National Coverage Determination (NCD) released today on Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer. The association and other stakeholders submitted extensive comments to the agency on the proposed NCD to ensure that the policyContinue Reading »...
  • ACLA Evaluating CMS’ Final National Coverage Determination on Next Generation Sequencing

    March 16, 2018
    (Washington, D.C.) – The American Clinical Laboratory Association (ACLA) stated that it is reviewing the Centers for Medicare & Medicaid Services (CMS) final National Coverage Determination (NCD) released today on Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer. The association had previously voiced concerns in response to the proposed NCD, cautioning that it would deprive Medicare beneficiaries of access to critical laboratoryContinue Reading »...
  • ACLA Leads Clinical Laboratory Community in Urging CMS to Address State Medicaid Rate Cuts for Lab Services

    March 09, 2018
    (Washington, D.C.) – The American Clinical Laboratory Association (ACLA) along with a dozen clinical laboratory stakeholders sent a letter to Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma today urging her to discourage states from making cuts to Medicaid rates for lab tests. The letter notes that with the flawed implementation of the Protecting Access to Medicare Act (PAMA) significantly reducing MedicareContinue Reading »...
  • Rep. Diana DeGette to Open ACLA 2018 Annual Meeting with a “View from Capitol Hill”

    February 02, 2018
    (Washington, D.C.) – The American Clinical Laboratory Association (ACLA) announced today that Rep. Diana DeGette (D-CO) will open the organization’s annual meeting on March 6th in Washington, D.C. with an overview of Congress’s 2018 agenda, specifically actions that may impact the clinical laboratory community. A recognized leader in policy impacting diagnostic innovation and its role in precision medicine, DeGette was instrumental in passing theContinue Reading »...
  • ACLA Submits Comments on Next Generation Sequencing National Coverage Determination

    January 17, 2018
    (Washington, D.C.) – The American Clinical Laboratory Association (ACLA) today submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed national coverage determination (NCD), “Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer.”  In its comments, the association expressed support for Foundation Medicine’s original request for a NCD for its comprehensive genomic profiling test, but voiced deep concern withContinue Reading »...
  • ACLA NGS NCD comments

    January 17, 2018
    ...
1 2 3 4